INVO Fertility Reports Second Quarter 2025 Earnings
INVO Fertility (NASDAQ:IVF) Second Quarter 2025 Results
Key Financial Results
Net loss: US$3.21m (flat on 2Q 2024).
US$8.07 loss per share.
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
All figures shown in the chart above are for the trailing 12 month (TTM) period
INVO Fertility Earnings Insights
Looking ahead, revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are down 13% from a week ago.
Risk Analysis
Before you take the next step you should know about the 6 warning signs for INVO Fertility (3 are potentially serious!) that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
9 minutes ago
- Fox News
Who Are The 10 Highest-Paid NFL Players Entering The 2025 Season?
Kansas City Chiefs quarterback Patrick Mahomes may have won two Super Bowls in the past three seasons, but he's not one of the 10 highest-paid players in the NFL in terms of average annual value (AAV). In some cases, talent doesn't equate to money. For others, however, constant production has certainly led to big pay days. This offseason has been one for the books, and a lot of money has exchanged hands this summer. That said, we rounded up the highest-paid players in the league entering the 2025 season. Some players unfortunately see drops in their production after signing long-term, big-money contracts. Jackson, however, isn't one of those players. He signed a five-year extension worth $260 million in April 2023 and followed that up with an MVP-winning season. He then improved once again in 2024, throwing for a career-high 4,172 yards and 41 touchdowns last season, although he fell short of a third MVP award. Herbert signed a five-year, $262 million deal in the summer of 2023 before enduring a porous season that was cut short after he fractured his right index finger. Herbert bounced back in 2024, leading the Chargers back to the playoffs. Herbert is now entering his sixth NFL season and is still in search of his first postseason victory. Purdy was a consistent cog in the 49ers' run to Super Bowl LVIII in 2024. He signed a five-year, $265 million deal in May, and now that he has his long-term money, it's time to show that he can lead a team. It'll be especially important for the 49ers' success this season, as they moved on from wide receiver Deebo Samuel and will be without wideout Brandon Aiyuk until at least Week 6. Therefore, the extent of Purdy's individual ability will finally be determined. Goff signed a four-year contract worth $212 million in May 2024. It was a respectable nod from the Lions, who rebuilt around Goff and are now contending with him at the epicenter of their system. Last season, Goff led the Lions to a franchise-best 15 wins, throwing for 4,629 yards and a career-high 37 touchdowns. It'll be interesting to see how Goff fairs now that former offensive coordinator Ben Johnson has moved on to become the Chicago Bears' head coach. Tagovailoa signed his four-year, $212 million extension in July 2024 following a season in which he threw for a career-high 4,624 yards and 29 touchdowns, but his career has been marred by a bevvy of unfortunate concussions, and he sustained one last season that forced him to miss four games early in the season. When he returned, he wasn't his normal, dynamic self, as his yards per pass attempt dropped to 7.1 and his yards per completion dropped to 9.5. To make good on his contract, Tagovailoa will have to remain healthy and return to his old form. Lawrence was one of those players whose production dipped after he signed a big extension — after inking a five-year, $275 million deal in July 2024, he threw for a career-low 204.5 yards per game. His season was shortened to just 10 games by a pair of injuries (an AC joint sprain in his left shoulder and a concussion), but those injuries came after the dip in play, so it'll be interesting if Lawrence can return to the form he showed early in his career. It'll help to have a new coaching regime in Jacksonville — with offensive-minded head coach Liam Coen coming over from Tampa Bay. After signing a five-year, $275 million deal, Burrow played just 10 games in the 2023 season because of a wrist injury. Last year, though, he reminded everyone just how valuable he is, leading the NFL with 4,918 yards and 43 passing touchdowns — numbers that certainly would have won him MVP honors had his team not severely underachieved. The Packers took a leap of faith, signing Love to a four-year, $220 million deal after just one season with him as their starter. It was a pretty impressive campaign in 2023; Love threw for 4,159 yards and 32 touchdowns and led the Packers to the NFC divisional round. Things came back down to earth in 2024, however, as Love threw for 3,389 yards and 25 scores. He was playing through an MCL sprain and a groin injury, so that could be to blame for the dip in play. This season, he'll have to prove if it truly was the injuries holding him back from being a perennial superstar. Allen, one of the most talented quarterbacks in the league, won the 2024 NFL MVP award after signing a six-year, $330 million extension with the Bills in the offseason. Last season was especially impressive for Allen because he lost top wide receiver Stefon Diggs and still shined with a combined 40 touchdowns. The only thing missing from Allen's résumé is a Super Bowl appearance — and victory. It's fitting that Prescott tops this list, as he is the quarterback for the NFL's most extravagant team. It's also ironic, as owner Jerry Jones isn't exactly complying to pay another one of their stars, Micah Parsons. Prescott signed a four-year, $240 million deal on the first Sunday of the 2024 NFL season. Maybe Jones will do the same with Parsons this season? Prescott was impressive in the season before signing his extension. In 2023, he completed an NFL-best 410 passes, and led the league with 36 touchdowns. Last year, however, his completion percentage dropped five points to 64.7%. He threw for a career-low 10.7 yards per completion, before sustaining a season-ending hamstring injury. With the addition of wide receiver George Pickens to a receiving core that already has CeeDee Lamb, Prescott should have every opportunity to show why he's the highest-paid quarterback in the league this season. Check out all of our Daily Rankers. Want great stories delivered right to your inbox? Create or log in to your FOX Sports account, follow leagues, teams and players to receive a personalized newsletter daily!
Yahoo
30 minutes ago
- Yahoo
Green Hydrogen Production Group Closes on Major Investment
A California-based hydrogen production group said it has completed a funding round in support of the company's first 100-kilotonne carbon dioxide removal (CDR) commercial facility. Equatic, which is considered a pioneering company in combined carbon dioxide removal and green hydrogen production, on August 11 announced the successful closure of its Series A round, with Catalytic Capital for Climate and Health (C3H) leading an $11.6-million investment. C3H is a catalytic vehicle by Temasek Trust, along with Kibo Invest, a Singapore-based private investment office with a focus on climate technology. The funding round, with participation from a consortium of global investors, will accelerate the engineering scale-up and commercialization of Equatic's patented seawater electrolysis technology. This substantial capital infusion will support the ongoing engineering of Equatic's CDR commercial facility, alongside further commercialization, manufacturing, and technological development. Equatic's proprietary technology is designed to capture atmospheric carbon dioxide and produce green hydrogen in a single, scalable process, advancing two critical net-zero pathways. 'This investment marks a pivotal moment for Equatic, enabling us to significantly scale our production capabilities and accelerate our mission to deliver durable carbon removal at scale,' said Gaurav N. Sant, founder and chief technology officer for Equatic. 'The Temasek Trust ecosystem has been a foundational partner to Equatic, from early-stage philanthropic backing from Temasek Foundation to catalytic investment through C3H. We welcome Kibo Invest as co-lead and recognize their commitment to invest in companies that are revolutionizing industries and addressing urgent climate challenges.' 'Truly innovative carbon management technologies are needed to mitigate climate change before the consequences become irreversible,' said Lord John Browne, chairman of Equatic's advisory board. Browne also is founder and chairman at BeyondNetZero, and the former CEO of British Petroleum. 'By removing carbon dioxide and simultaneously generating green hydrogen, Equatic's solution provides unique advantages in terms of cost and scalability.' Ryan Tan, head of C3H, said, 'Equatic's technology and approach exemplify the type of bold and scalable innovation that aligns with C3H's mandate. We are delighted to support Equatic's goal in advancing promising climate mitigation solutions that offer permanent, durable carbon removal with green hydrogen production for scalable, tangible impact and commercial benefit.' 'Equatic represents an exciting opportunity to scale deep-tech innovation that addresses two critical needs: decarbonisation and clean energy. As an investor focused on climate solutions, we are proud to partner with C3H and Equatic to help bring this breakthrough technology to commercial scale,' said James Marshall, CEO of Kibo Invest. Equatic's Technology Since commencing operations in 2023, the Equatic technology has been successfully deployed at two pilot plants in Los Angeles and Singapore. The company is now expanding its operations with a demonstration plant in Singapore, known as Equatic-1, and a commercial-scale plant in Canada. In May 2024, Equatic was recognized as a CDR Purchase Prize semifinalist by the U.S. Department of Energy, acknowledging its high-quality, permanent carbon credits and rigorous Monitoring, Reporting, and Verification (MRV) practices. In September 2024, Equatic announced a significant climate breakthrough with the U.S. manufacture of oxygen-selective anodes, which unlock scalable hydrogen production through direct seawater electrolysis. That same month, Equatic was named a finalist for The Earthshot Prize, a prestigious international recognition for groundbreaking solutions to repair the planet. Equatic's commitment to high-integrity carbon removal is underscored by its adoption of an ISO-14064 standard for MRV, first published by Equatic in May 2023. Subsequently, this standard was validated by two leading carbon removal registries, Isometric and making Equatic one of the only marine companies capable of issuing high-quality CDR credits under either registry, with full transparency and auditability. Buyers of Equatic's CDR credits include Boeing, a leading global aerospace company and other large industrial companies committed to market-based mechanisms for decarbonization. —POWER edited this content, which was contained in a press release from Equatic.
Yahoo
35 minutes ago
- Yahoo
Mizuho Lowers PT on Acadia Healthcare Company (ACHC) to $22 From $32, Keeps a Neutral Rating
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the top cheap stocks that will go to the moon according to Reddit. On August 14, Mizuho analyst Ann Hynes lowered the firm's price target on Acadia Healthcare Company, Inc. (NASDAQ:ACHC) to $22 from $32, keeping a Neutral rating on the shares. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. The rating update came after Acadia Healthcare Company, Inc. (NASDAQ:ACHC) reported fiscal Q2 results that missed consensus estimates when excluding the incremental effect of direct provider payments in the quarter. The firm slashed its 2025-2027 adjusted EBITDA estimates and is staying on the sidelines, attributing the stance to 'execution missteps' and uncertainty regarding the effects of the ongoing Medicaid Redeterminations and the One Big Beautiful Bill Act. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services across the US in various settings, including inpatient psychiatric hospitals, residential treatment centers, specialty treatment facilities, and outpatient clinics. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
